Browse by author
Lookup NU author(s): Dr Emily Shaw, Dr Fiona Black
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2021, The Author(s).Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.
Author(s): Lindsay CR, Shaw EC, Moore DA, Rassl D, Jamal-Hanjani M, Steele N, Naheed S, Dick C, Taylor F, Adderley H, Black F, Summers Y, Evans M, Rice A, Fabre A, Wallace WA, Nicholson S, Haragan A, Taniere P, Nicholson AG, Laing G, Cave J, Forster MD, Blackhall F, Gosney J, Popat S, Kerr KM
Publication type: Review
Publication status: Published
Journal: British Journal of Cancer
Year: 2021
Volume: 125
Pages: 1210-1216
Print publication date: 26/10/2021
Online publication date: 06/09/2021
Acceptance date: 16/04/2021
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
Publisher: Springer Nature
URL: https://doi.org/10.1038/s41416-021-01407-9
DOI: 10.1038/s41416-021-01407-9
